Diclotas® Gel 30g/1.05oz

Diclofenac 1.16% Topical

USD $16.00

Diclotas topical gel is manufactured by Intas Pharmaceuticals. The gel contains the main ingredient Diclofenac (Voltaren Emulgel and Traumeel gel alternative) is a nonsteroidal anti-inflammatory drug which is successfully used to relieve joint pain from arthritis.

Diclotas with Diclofenac 1.16% gel works by reducing substances in the body that cause pain and inflammation. Diclofenac is used to relieve pain, swelling (inflammation), and joint stiffness caused by arthritis. Reducing these symptoms helps you do more of your normal daily activities. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID).

Brand name: Voltaren Emulgel, Traumeel Gel
Items:3 - 5 5%
Items:6 - 9 10%
Items:10 + 15%


What is Diclofenac Diclotas® gel (Voltaren Emulgel alternative)

Diclofenac topical (Voltaren Emulgel alternative, Traumeel gel) is used to treat joint pain caused by osteoarthritis, is for use on the knees, hands, wrists, elbows, ankles, or feet. This medicine may not be effective in treating arthritis pain elsewhere in the body. Diclotas gel (Voltaren Emulgel, Traumeel gel) Diclofenac gel price is always available to check in the okdermo.com website.

Diclofenac is used to treat pain and other symptoms of arthritis of the joints (eg, osteoarthritis), such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not cure osteoarthritis and will help you only as long as you continue to use it. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID). Diclofenac topical 1.16% gel is also used to treat actinic keratosis, a skin problem that may become cancerous if not treated. The exact way that topical diclofenac helps this condition is unknown.

Diclofenac topical solution is used to treat pain and swelling caused by osteoarthritis of the knees. Diclofenac topical is used to treat acute pain caused by minor strains, sprains, and contusions (bruises).

Main ingredients of Voltaren Emulgel / Diclofenac Diclotas® gel

Diclotas (Diclofenac sodium topical gel over the counter) gel contains the following main ingredient – Diclofenac Diethylamine 1,16% – is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammatory diseases such as gout. It is applied to the skin. Improvements in pain typically occur within half an hour and last for as much as eight hours.

Brand name: Voltaren Emulgel, Traumeel gel, Cataflam, Zipsor, Flector, Pennsaid, Rexaphenac, Solaraze, Cambia, Zorvolex, Nonsteroidal anti-inflammatory drug, Diclofenac gel, Diclofenac sodium, Biofreeze, Bengay, Icy hot, Dynapar.


Intas Pharmaceuticals

The Biologics Business Unit (BU) of Intas Pharmaceuticals Limited was formerly an independent biotechnology company and was known as Intas Biopharmaceuticals Ltd. Intas Pharmaceuticals Limited is an Indian company headquartered in Ahmedabad, India. The Biologics BU is located in Moraiya, Ahmedabad and is one of the leading biosimilar product manufacturers in Asia. Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company headquartered in India. Intas' success and incessant growth lies in clinical execution of successful and strategic moves made in the areas of manufacturing, R&D, Biotechnology and global operations over three decades. As on 31st of March 2018, Intas has recorded a global turnover of $1.7 billion at >20% CAGR over the last 5 years. Intas is currently ranked 11th in the Indian Pharma Market with 2.9% market share*. In the domestic market, Intas enjoys a leadership position in chronic therapies such as Neurology, Psychiatry, Cardiovascular, Diabetes, Oncology, Urology, Nephrology, Rheumatology & Gynecology, Infertility, Gastroenterology, Pain Management and healthy presence in other major therapeutic segments. Besides well-established domestic prominence, Intas is also present in more than 80 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Africa, Australia, New Zealand, Asia-Pacific as well as CIS and MENA countries. Intas' global strategy includes alliances with leading Global Pharma Companies for the development and distribution of products as well as direct product distribution. The company is known for its range of products in Oncology and other hospital-based therapeutic segments in the EU and US. After the landmark acquisition of Teva's assets, Intas has become a leading player in the generics market in the UK. Intas' success and growth is a direct influence of Intas' extensive R&D capabilities, its manufacturing abilities, and its people. Every year, the company invests around 6-7% of its revenues in R&D. Besides building the regular portfolio of generic products, Intas' R&D is also focused on creating a pipeline of novel drug delivery technology-based products and biologics and has invested over $125 million to develop and enhance its biosimilar capabilities over the past 8 years. Intas operates fourteen formulation manufacturing facilities, of which seven are located in India, and the rest in the U.K. and Mexico. Two of their flagship facilities are accredited by top global regulators such as USFDA, EMA, MHRA, TGA, etc. It is also the first company in India to have its biologics manufacturing facility accredited by the European Health Authority. Intas operates sixteen formulation manufacturing facilities, of which eleven are located in India, and the rest in the U.K. and Mexico. It also operates two API and intermediate manufacturing facilities, each of which complies with the regulatory requirements in the jurisdictions in which it operates. Between them, these facilities have received approvals from various prominent international regulatory bodies, including from U.S. Food and Drug Administration (FDA). Each of Intas' manufacturing facilities is designed, equipped and operated to deliver high-quality products within defined cost and delivery schedules. These manufacturing facilities have the flexibility to operate in various dosage forms and a wide range of batch sizes. Intas' world class oncology formulation facility operates under global regulatory and safety standards. The Ahmedabad SEZ caters exclusively to the US, Europe and other regulated markets. A highly advanced upcoming facility in Ahmedabad, Gujarat is set to double Intas' manufacturing capabilities.


Diclofenac Diethylamine 1,16%

Gel base q.s.


There are no reviews yet.

Be the first to review “Diclotas® Gel 30g/1.05oz”

Your email address will not be published. Required fields are marked *